US Food and Drug Administration leadership recently stressed the importance of the rare pediatric disease priority review voucher program, a notable shift for the agency, which once said the program had adversely impacted its ability to set public health priorities and manage its workload, just as the program heads toward its reauthorization deadline.
FDA Leadership Changes Tune On Pediatric Priority Review Voucher Benefit
As the reauthorization deadline nears, CDER and CBER leaders stressed that sunsetting the program would hurt pediatric rare disease development, while endorsing a new Democrat-proposed stick for rare disease research.
